Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc operates within a growing market, as total ADHD medication sales in the U.S. have increased by approximately 8% annually since 2010, reaching around $18 billion in 2020. The company has demonstrated promising results from the CTx-1301 clinical trials, with positive topline data indicating a favorable effect compared to placebo in subjects. These factors underscore the potential for substantial growth and highlight the company's capability to address unmet needs in ADHD treatment, contributing to a positive outlook for Cingulate's stock.

Bears say

Cingulate Inc reported a net loss of $4.8 million with an EPS of $(1.09), which exceeded negative estimates and consensus expectations for the quarter, reflecting challenges in financial performance. Additionally, the company faced a more significant net loss of $7.3 million in a subsequent period, underscoring ongoing operational difficulties and exceeded earlier estimations for losses. The analysis highlights critical risks including balance sheet and liquidity concerns, potential clinical trial failures, regulatory setbacks, and competitive pressures, collectively contributing to a negative outlook for the stock.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.